Copyright © 2024 Research Nester. All Rights Reserved
Migraine Drugs Market size was over USD 5.57 billion in 2023 and is projected to reach USD 23.2 billion by 2036, growing at around 11.6% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of migraine drugs is assessed at USD 6.09 billion.
The major key factors projected to drive the growth of the market include rise in the prevalence of migraines, stressed lifestyle along with rising healthcare expenditure. Since, numbers of migraine incidences are increasing and order to meet the unmet demand in migraine drugs, most of the companies are investing in research and development areas pertaining to migraine drugs. Further, novel product innovations and development of new devices for the new treatment options for migraine is anticipated to accelerate the growth of the market over the forecast period.
Growth Drivers
Increase in the Female Population
Migraines are more frequent in women as compared to men. This migraine in women’s is assigned to the rising and falling levels of estrogen during menstruation, menopause and pregnancy. Further, before puberty the prevalence of migraine in males and females remains same, however the first migraine in females occur when their periods begin and after puberty, it increases in females almost three times than males. Therefore, with the increase in the population of females, number of migraineurs is anticipated to increase, thus, driving the growth of the market.
Increase in Awareness regarding Migraine
The rising awareness related to migraine and the drugs available for its treatment is one of the major factors accelerating the growth of market. A number of organisations, such as, American Headache Society, are taking measures to spread awareness related to migraine therapeutics and to provide support to the patients regarding the disorders related to headache. Moreover, financial burdens and bad environmental conditions are increasing the demand to cure stress and to aware people about mental health. Hence, awareness about migraine is estimated to drive the growth of market over the forecast period.
Challenges
Different Side Effects from Migraine drugs
Migraine treatment includes acute therapy and preventive therapy. Since, patients want to get faster or complete relief, without any adverse affects or drugs. However, frequent use of some medications can lead to the happening of disabling condition in the patients. The side effects of the medications depend on the specific drug. Taking multiple drugs together can cause excess of serotonin in the human body leading to life threatening conditions. Hence, side effects of the migraine drugs are likely to hamper the market growth over the forecast period.
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
11.6% |
|
Base Year Market Size (2023) |
USD 5.57 billion |
|
Forecast Year Market Size (2036) |
USD 23.2 billion |
|
Regional Scope |
|
The treatment type segment in migraine drugs market is segmented into abortive treatment and preventive treatment. Based upon segmentation by treatment type, the market for abortive segment is anticipated to dominate the market on the account of ease of self administration for the people having vomiting or nausea related to migraine. In addition, abortive treatment works quickly when used at the first sign of migraine. These factors are forecasted to drive the growth of the market.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Treatment Type |
|
|
By Route of Administration |
|
|
By End Users |
|
On the basis of regional analysis, the migraine drugs market is segmented into five major region including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market for migraine drugs in North America industry is estimated to hold largest revenue share by 2036, due to increasing adoption of novel therapies and high prevalence of migraine.The Asia Pacific is projected to see significant growth in future on the account of rising demand for better healthcare services along with the contribution from the major developing economies such as India and China towards migraine drugs. Moreover, large undeserved patient population and high penetration from drug manufacturers is adding up to the key factors driving the growth of the market in the region over the forecast period.
On February 15, 2020, a new prescription medication Reyvow was approved by the Drug Enforcement Application (DEA) to provide treatment for acute migraines and associated symptoms such as nausea and sensitivity to light & sound. This medicine is especially for patients having disabling problems and who do not respond to medicines.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?